SAN JOSE, Calif., March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II ( ...

Core Insights - Anixa Biosciences, Inc. is set to present at the 2025 Cancer Advocacy Group of Louisiana NeauxCancer Conference, highlighting its advancements in cancer treatment and prevention [1][2] - The presentation will focus on Anixa's CAR-T therapy for solid tumors and novel cancer vaccine initiatives, showcasing the company's progress in clinical development and next-generation immunotherapies [2] Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company is also developing vaccines in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [4] - Anixa's business model involves collaboration with renowned research institutions throughout all stages of development, allowing for the exploration of emerging technologies for further development and commercialization [4]

Revenue Performance - Revenue for the three months ended January 31, 2025, was $0, consistent with the same period in 2024[81]. - The company does not expect to begin generating revenue from its current therapy or vaccine programs in the near term[82]. Expenses - Research and development expenses increased by approximately $203,000 to approximately $1,552,000 for the three months ended January 31, 2025, compared to approximately $1,349,000 in the same period in 2024[84]. - General and administrative expenses decreased by approximately $426,000 to approximately $1,834,000 for the three months ended January 31, 2025, from approximately $2,260,000 in the same period in 2024[86]. - Interest income decreased by approximately $146,000 to approximately $173,000 for the three months ended January 31, 2025, from approximately $319,000 in the same period in 2024[87]. Assets and Cash Flow - Total current assets decreased by approximately $2,676,000 to approximately $18,686,000 as of January 31, 2025, compared to approximately $21,362,000 at October 31, 2024[90]. - Cash used in operating activities was approximately $2,904,000 for the three months ended January 31, 2025[91]. - Cash provided by investing activities was approximately $2,703,000, resulting from the maturities of short-term investments of approximately $15,700,000[91]. - The company has approximately $97 million of common stock available for sale under its at-the-market equity program as of January 31, 2025[90]. Net Loss - The net loss attributable to noncontrolling interest decreased by approximately $6,000 to approximately $29,000 for the three months ended January 31, 2025[88].

Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer treatment and prevention [3] - The company has a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, utilizing chimeric endocrine receptor-T cell (CER-T) technology [3] - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer, developed in collaboration with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [3] - The company partners with renowned research institutions to explore emerging technologies for further development and commercialization [3] Upcoming Events - Anixa will host its 2025 Annual Meeting of Stockholders on March 20, 2025, at 10:00 a.m. Pacific Time in a virtual format [1] - Following the formal business and voting portion, Anixa's Chairman and CEO, Dr. Amit Kumar, will deliver an investor presentation and corporate update, followed by a Q&A session [2] - Interested parties can access the meeting online at www.virtualshareholdermeeting.com/ANIX2025 [2]

Core Viewpoint - Anixa Biosciences, Inc. is actively participating in the Alliance for Cancer Gene Therapy Summit 2025, highlighting its advancements in cancer treatment, particularly in cell and gene therapy for gynecologic and breast cancers [1][2][3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is also developing vaccines in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [5] - Anixa employs a unique business model that involves partnering with renowned research institutions throughout all stages of development, allowing for the exploration of emerging technologies in complementary fields [5] Event Participation - Dr. Pam Garzone, Chief Development Officer of Anixa, will be a panelist at the ACGT Summit, discussing advancements in cell and gene therapy, including Anixa's CAR-T therapy for ovarian cancer [2][3] - The panel discussion is scheduled for March 19, 2025, from 11:15 AM to 12:15 PM ET, at the Alexandria Center for Life Science in New York City [1][2]

Core Insights - Anixa Biosciences has completed dosing its final patient in the third cohort of a Phase 1 clinical trial for its CAR-T therapy targeting recurrent ovarian cancer, in partnership with Moffitt Cancer Center [1][4] - The third cohort received a dose of one million CAR-positive cells per kilogram, a tenfold increase from the first cohort, with the fourth cohort set to increase the dosage by another factor of three [2][3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is also developing vaccines for breast and ovarian cancer in partnership with Cleveland Clinic, targeting various cancers through innovative immunization strategies [5] Clinical Trial Details - The ongoing trial (NCT05316129) is designed to evaluate the safety and efficacy of the CAR-T therapy in adult women with recurrent ovarian cancer who have not responded to at least two prior therapies [3] - Recent protocol amendments allow eligible patients to receive a second dose without requiring separate IND approvals, expanding the enrollment criteria to include rare ovarian cancer subtypes [4]

Core Viewpoint - Anixa Biosciences' breast cancer vaccine has the potential to revolutionize breast cancer prevention by targeting the disease at its earliest stages, as highlighted in a feature on Fox News' "America Reports" [1][3] Company Overview - Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program and vaccines for breast cancer and other malignancies [5] Vaccine Development - The breast cancer vaccine is designed to train the immune system to recognize and eliminate cancerous cells before they develop into invasive tumors, specifically targeting the lactation protein α-lactalbumin, which is expressed in malignant breast cancer cells [2] - The Phase I clinical trial, conducted in collaboration with Cleveland Clinic and funded by a U.S. Department of Defense grant, shows promising progress with over 70% of patients demonstrating protocol-defined immune responses [3] Future Plans - A Phase 2 study in the neoadjuvant setting is planned to begin in 2025, representing a critical milestone in the vaccine's continued development [3]

Core Insights - Anixa Biosciences, Inc. will participate in the 18th Annual European Life Sciences CEO Forum to discuss its innovative cancer therapies [1][2][4] - The company is focusing on its CAR-T therapy for ovarian cancer and a breast cancer vaccine, developed in collaboration with leading research institutions [2][4] Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention [4] - The company’s pipeline includes a novel CAR-T therapy for ovarian cancer and vaccines for breast cancer and other hard-to-treat cancers [4] Event Details - The 18th Annual European Life Sciences CEO Forum will take place on February 26-27, 2025, at the Hilton Zurich Airport Hotel [6] - Mike Catelani, President and CFO, will present at the event and engage in one-on-one meetings with potential partners and investors [3][6]

Core Insights - Anixa Biosciences is focused on pioneering efforts in breast cancer prevention, specifically through the development of a novel vaccine targeting triple-negative breast cancer (TNBC) [1][2][3] Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center [5] - The company is developing vaccines in partnership with Cleveland Clinic to address breast cancer and ovarian cancer, as well as other cancers such as lung, colon, and prostate [5] Research and Development - The vaccine under development aims to prevent TNBC by targeting a specific protein found in TNBC cells, which is absent in normal breast tissue, thereby stimulating the immune system to eliminate cancer cells before tumor formation [2][3] - Dr. Amit Kumar emphasized the potential of the vaccine to change the approach to breast cancer treatment, potentially reducing the need for invasive procedures like chemotherapy and surgery in the future [3] Industry Impact - The discussion highlighted the broader implications of Anixa's research on oncology and the critical need for continued innovation in cancer prevention [3]

Core Insights - Anixa Biosciences has made significant progress in developing innovative cancer therapies and vaccines in 2024, while maintaining a strong financial position for future growth [1][8] Financial Performance - The company utilized only $7 million in cash during the 2024 fiscal year, ending with $20 million in cash and investments, ensuring a strong balance sheet for advancing programs [2] - Anixa has a cash runway of over 2.5 years, supported by a clean capital structure free of warrants, preferred stock, and debt [5] Clinical Developments - Positive preliminary Phase 1 data from the breast cancer vaccine trial was presented at the SITC conference, showing a strong safety profile with over 70% of patients exhibiting protocol-defined immune responses [2][6] - The company is expanding its vaccine programs to include prostate, lung, and colon cancers, alongside ongoing collaboration with the National Cancer Institute for the ovarian cancer vaccine [3] - The CAR-T program targeting ovarian cancer has shown promising results, with a patient from the first dose cohort receiving FDA authorization for a second dose and remaining well 21+ months post-treatment [4] Future Goals - Plans for 2025 include completing the Phase 1 trial of the breast cancer vaccine, initiating the Phase 2 trial, and advancing CAR-T clinical trials for additional solid tumors [7] - Continued development of vaccines for ovarian, lung, prostate, and colon cancers is expected, with progress updates throughout the year [7]